---
layout: default
title: Atropine Sulfate
parent: 僅模型預測 (L5)
nav_order: 48
evidence_level: L5
indication_count: 0
---

# Atropine Sulfate
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Atropine Sulfate: Repurposing Candidate — Data Insufficient for Full Evaluation

## One-Sentence Summary

Atropine Sulfate is a well-established anticholinergic agent with broad clinical applications including bradycardia management, organophosphate poisoning antidote, and mydriasis induction.
The current Evidence Pack contains **no TxGNN-predicted indications**, and critical data fields — including mechanism of action, safety warnings, and regulatory records — are all absent.
This report documents the data gaps and recommends a **Hold** pending remediation before any repurposing evaluation can proceed.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not available in Evidence Pack |
| Predicted New Indication | Not available — no TxGNN predictions returned |
| TxGNN Prediction Score | N/A |
| Evidence Level | N/A — no predictions or supporting studies on file |
| Taiwan Market Status | ✗ Not Marketed (0 licenses found) |
| Number of Authorizations | 0 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

No TxGNN predictions are available for this drug at this time; therefore, a mechanism-to-indication linkage analysis cannot be performed.

Currently, detailed mechanism of action data is not available in the Evidence Pack. Based on established pharmacology, Atropine Sulfate is a competitive antagonist at muscarinic acetylcholine receptors, producing effects including increased heart rate, reduced secretions, smooth muscle relaxation, and pupil dilation. These properties underpin its classical uses across emergency medicine, anaesthesia, and ophthalmology.

To determine whether a repurposing prediction is pharmacologically reasonable, TxGNN outputs are required. Once predictions are returned, the anticholinergic mechanism can be assessed for relevance to any predicted indication.

---

## Clinical Trial Evidence

Currently no related clinical trials registered in the Evidence Pack.

---

## Literature Evidence

Currently no related literature available in the Evidence Pack.

---

## Taiwan Market Information

No authorizations on file. TFDA query returned 0 results for ATROPINE SULFATE as of 2026-03-29.

---

## Safety Considerations

Please refer to the package insert for safety information.

> A TFDA package insert query returned 1 result (query log ID 4, status: success), but its contents have not been parsed into the Evidence Pack. Retrieving warnings and contraindications from this source is the highest-priority remediation action (DG001, Blocking severity).

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The Evidence Pack is missing all three elements required to begin a repurposing evaluation: TxGNN predictions, mechanism of action data, and safety information. No assessment of efficacy, risk, or regulatory pathway is possible at this stage.

**To proceed, the following is needed:**

- **\[Blocking\]** Parse the TFDA package insert (query log ID 4 already returned success) to extract warnings, contraindications, and approved indications — this unblocks S1 safety screening (DG001)
- **\[High\]** Retrieve DrugBank MOA data (query log ID 3 returned 1 result) to enable mechanism-indication linkage analysis (DG002)
- **\[Critical\]** Re-run TxGNN prediction pipeline for ATROPINE SULFATE — the `predicted_indications` array is empty, which prevents any repurposing evaluation from proceeding
- **\[Informational\]** Confirm whether the 0-result TFDA license search reflects a genuine absence of Taiwan approvals or a query configuration issue, given that Atropine Sulfate is widely marketed globally
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

